Abstract
Erythrocytosis is characterized by an abnormally high concentration of red blood cells, often resulting from bone marrow disorders or defects in oxygen-sensing pathways. However, many cases remain "idiopathic" after standard clinical screening. We report the identification of a novel heterozygous missense mutation (c.269G>A; p.Arg90His) in the BPGM gene in a 27-year-old male with unexplained erythrocytosis. Bisphosphoglycerate mutase (BPGM) is responsible for the synthesis of 2,3-bisphosphoglycerate (2,3-BPG), a key regulator of hemoglobin-oxygen affinity. Our findings demonstrate that the R90H mutation reduces BPGM enzymatic activity and 2,3-BPG levels, leading to increased oxygen affinity and a compensatory overproduction of erythropoietin and red blood cells.
Introduction
Erythrocytosis presents a significant diagnostic challenge. While primary causes like Polycythemia Vera (often driven by JAK2 mutations) and secondary causes like chronic hypoxia or VHL mutations are well-documented, a subset of patients presents with high hemoglobin and hematocrit levels of unknown origin. In this study, we investigated a 27-year-old male with a hemoglobin level of 193 g/L. Despite five years of clinical investigation, standard tests for common genetic drivers were negative. This case highlights the utility of whole-genome sequencing (WGS) in uncovering rare genetic variants in metabolic pathways that influence oxygen delivery.
Methods
As part of the WGS500 Project, we performed whole-genome sequencing on the patient using the Illumina HiSeq2000 platform. Bioinformatics analysis utilized STAMPY for mapping and Platypus for variant calling, with a specific focus on genes involved in red blood cell regulation. To validate the findings, we performed Sanger sequencing on the patient and his parents. We also conducted biochemical assays to measure BPGM enzyme activity and 2,3-BPG concentrations in red blood cells. Finally, structural modeling was performed using PyMOL and the known crystal structure of human BPGM (PDB: 2HHJ) to assess the impact of the identified mutation on protein stability.
Results and Genetic Discovery
Whole-genome sequencing identified a novel heterozygous missense mutation in the BPGM gene (c.269G>A), resulting in an Arginine-to-Histidine substitution at residue 90 (p.Arg90His). Sanger sequencing confirmed that the patient inherited this mutation from his mother, while his father carried the wild-type allele.
Clinical phenotyping revealed a significant "leftward shift" in the oxygen dissociation curve, with a $P_{50}$ of 23.91 mmHg (normal range: 27–33 mmHg). Biochemical analysis showed that the patient’s BPGM activity was reduced to 3.62 IU/g Hb (Control: 4.99) and 2,3-BPG levels were nearly halved at 14.5 µmol/g Hb (Control: 27.6). Interestingly, while the mother carried the same mutation and showed reduced 2,3-BPG levels, she did not exhibit clinical erythrocytosis, suggesting variable penetrance.
Molecular Mechanism
2,3-BPG is essential for stabilizing the deoxygenated (T-state) form of hemoglobin, which facilitates oxygen release to tissues. The R90 residue in BPGM is located near the active site and is critical for stabilizing the protein's structure through a network of hydrogen bonds.
Modeling suggests that replacing the positively charged Arginine with Histidine disrupts these stabilizing bonds (e.g., with W115 and E156), destabilizing the active site pocket. This structural impairment explains the observed reduction in BPGM activity and the subsequent drop in 2,3-BPG levels. The resulting high oxygen affinity of hemoglobin leads to relative tissue hypoxia, triggering the kidneys to produce more erythropoietin (15.9 mIU/mL in the patient) and stimulating red blood cell production.
Conclusion
This study identifies a novel BPGM mutation as a cause of hereditary erythrocytosis. It underscores the importance of considering 2,3-BPG deficiency in the differential diagnosis of idiopathic erythrocytosis, especially when patients exhibit a high-affinity oxygen dissociation curve. We recommend that BPGM be included in genetic screening panels for unexplained erythrocytosis to improve diagnostic accuracy and patient management.
Summary updated